Boehringer and MD Anderson extend KRAS cancer collaborationBoehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring Share XBoehringer and MD Anderson extend KRAS cancer collaborationhttps://pharmaphorum.com/news/boehringer-and-md-anderson-extend-kras-cancer-collaboration/
Novartis’ canakinumab falls short in phase 3 lung cancer trialNovartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless Share XNovartis’ canakinumab falls short in phase 3 lung cancer trialhttps://pharmaphorum.com/news/novartis-canakinumab-falls-short-in-phase-3-lung-cancer-trial/
Merck & Co axes Keytruda lung cancer niche amid FDA crackdownMerck & Co has voluntarily withdrawn its Keytruda immunotherapy from a lung cancer niche in the US, amid Share XMerck & Co axes Keytruda lung cancer niche amid FDA crackdownhttps://pharmaphorum.com/news/merck-co-axes-keytruda-lung-cancer-niche-amid-fda-crackdown/
NICE backs NHS funding for MSD’s Keytruda combination in lung cancerNICE has backed regular NHS funding England and Wales for Merck, Sharp and Dohme’s Keytruda in combination with Share XNICE backs NHS funding for MSD’s Keytruda combination in lung cancerhttps://pharmaphorum.com/news/nice-backs-nhs-funding-for-msds-keytruda/
Not every cough is COVID – MSD UK’s lung cancer campaignFor World Cancer Day, David Long, business unit director of Oncology at MSD UK tells pharmaphorum about the Share XNot every cough is COVID – MSD UK’s lung cancer campaignhttps://pharmaphorum.com/views-analysis-oncology/world-cancer-day-msd-uk-lung-cancer-campaign/
AZ/Daiichi Sankyo’s partnership makes progress in lung cancerAstraZeneca and Daiichi Sankyo have announced data from two drugs in lung cancer, which they are developing as Share XAZ/Daiichi Sankyo’s partnership makes progress in lung cancerhttps://pharmaphorum.com/news/az-daiichi-sankyos-partnership-makes-progress-in-lung-cancer/
Doctors warn pandemic has pushed lung cancer services back 20 yearsGovernments must act to restore the damage done to lung cancer services during the pandemic in order to Share XDoctors warn pandemic has pushed lung cancer services back 20 yearshttps://pharmaphorum.com/news/pandemic-pushed-lung-cancer-services-back-20-years-leading-doctors-say/
GSK/Merck & Co’s hopeful bintrafusp alfa fails in key lung cancer trialGlaxoSmithKline’s big gamble on a cancer drug developed by Germany’s Merck KGaA looks unlikely to pay out, after Share XGSK/Merck & Co’s hopeful bintrafusp alfa fails in key lung cancer trialhttps://pharmaphorum.com/news/gsk-merck-cos-hopeful-bintrafusp-alfa-fails-in-key-lung-cancer-trial/
Scotland backs Roche’s Rozlytrek for ROS1 lung cancerThe Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of Share XScotland backs Roche’s Rozlytrek for ROS1 lung cancerhttps://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/
